Riskpilot← Back to searchSign inGet full accessUniphar Pharma Nordics AB
ABActiveOrg 5593663676StockholmTemporary employment agency activities and other human resource provisions · NACE 7820Est. 20221 employees
Revenue 2024
SEK 2,4M
-27% vs 2023
EBITDA margin
-83.1%
-6% vs 2023
Equity ratio
44.8%
Financial strength
Net profit 2024
SEK -2M
-6% vs 2023
| Revenue | SEK 2,4M | -27% |
| EBITDA | SEK -2M | -6% |
| Net profit | SEK -2M | -6% |
| Total assets | SEK 1,9M | -55% |
| Equity | SEK 841K | +477% |
| Employees | 1 | — |
Legal name
Uniphar Pharma Nordics AB
Org number
5593663676
Legal form
Aktiebolag
NACE code
7820 · Temporary employment agency activities and other human resource provisions
Founded
18 februari 2022
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska huvudsakligen tillhandahålla outsourcing och tjänster för tillhandahållande av resurser till tillverkare av farmaceutiska och medicinska anordningar och därmed förenlig verksamhet.
Address
Stockholm
Email
nordics@staroutico.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 2 233 | 3 274 | 2 395 |
| Staff expenses | — | — | — |
| EBITDA | −1 923 | −1 871 | −1 990 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | −1 923 | −1 871 | −1 990 |
| Net financials | — | — | 2 |
| Profit before tax | −1 923 | −1 871 | −1 988 |
| Tax | −0 | −0 | −0 |
| Net profit | −1 923 | −1 871 | −1 988 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 1 003 | 4 169 | 1 878 |
| Equity | −1 898 | −223 | 841 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 2 901 | 4 392 | 1 037 |
| Total debt | 2 901 | 4 392 | 1 037 |
EBITDA margin
-83.1%
This company
15.8%
Market median
-626% vs market
20222024
Equity ratio
44.8%
This company
38.2%
Market median
+17% vs market
20222024
Return on equity
-236.4%
This company
18.4%
Market median
-1385% vs market
20222024
Net profit margin
-83.0%
This company
8.1%
Market median
-1125% vs market
20222024
Asset turnover
1.28×
This company
1.12×
Market median
+14% vs market
20222024
Debt / equity
1.23×
This company
0.62×
Market median
-98% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SA Authorized Recipient of Service | Authorized Recipient of Service | 2025 |
| Former (1) | ||
KO Authorized Recipient of Service | Authorized Recipient of Service | 2024 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2024 | |
| Former (2) | ||
| Board of Directors | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Uniphar Pharma Nordics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Simon Aleksej Johannes Ringborg | Authorized Recipient of Service | 0 companies |
| Karl Olov Rickard Carrick | Authorized Recipient of Service | 0 companies |
| Padraic William Dempsey | Board of Directors | 0 companies |
| Timothy Dolphin | Board of Directors | 0 companies |
| Siobhan Brigid Taaffe | Deputy Board Member | 0 companies |
| Anna-Maria Helena Nyrén | Deputy Board Member | 0 companies |